Germany-based medical technology manufacturer Lifespin has teamed up with the Istanbul-based Acıbadem University (ACU) to establish an AI-driven metabolomics precision medicine platform.
Under the agreement, Lifespin and the ACU will establish a precision medicine platform which captures individual metabolomes using nuclear magnetic resonance (NMR) measurements combined with the use of AI algorithms.
The collaboration will help to deploy Lifespin’s products across the ACU’s network via a software as a service (SaaS) model, providing the technologies at competitive rates.
Metabolomics is the large-scale study of metabolites within cells. In certain diseases, the ratio of metabolites to each other differs distinctly from the standardised healthy baseline. Metabolite ratios can therefore serve as quantitative biomarkers for specific diseases. A metabolomics precision medicine platform analyses individual metabolic data to tailor personalised medical treatments.
Lifespin launched its first commercial product, the Lifespin Amino Acid Profiler (LAAP), in May 2023. The LAAP uses NMR to scan for hundreds of metabolites in a patient’s blood sample. A digital twin of the patient is then built using this information and compared to other patients’ profiles in the propriety database.
Lifespin aims to expand into Africa and the Arabian Peninsula according to the 28 May announcement. Speaking to Medical Device Network, Lifespin’s CEO Ali Tinzali previously emphasised that there is an opportunity for precision medicine adoption in the Middle East. He explained that many established organisations in the Western world struggle to keep up with the pace of change in AI and technology, whereas markets such as Hong Kong and the Emirates adapt to new technologies quickly.
The partnership also involves the creation of a regional data analysis, as well as a data production centre laboratory, which will support the global development and distribution of Lifespin's products.
Alongside the announcement accompanying the partnership, Tinzali said: "We are thrilled to collaborate with Acıbadem University to push the boundaries of AI-based precision medicine tools in the healthcare provider sector. Our combined efforts will not only advance medical technology but also make these tools for personalised medicine more accessible."
